Literature DB >> 24298491

Role of voglibose in the treatment of prediabetes in Indian population: a cross-speciality survey.

Pavitra Raj Dewda1, Sourabh Agrawal.   

Abstract

BACKGROUND: Prediabetes is a precursor of overt Type 2 Diabetes Mellitus (DM) and it is associated with insulin resistance and an increased risk for cardiovascular disease. ACE and AACE recommend only lifestyle modifications for the management of prediabetes. A recently published meta-analysis suggested that drug therapy was associated with a better control of diabetes. Voglibose was recently approved for the management of prediabetes in Japan.
MATERIAL AND METHODS: A well-structured questionnaire was sent to 117 doctors across India (52 diabetes specialists, 45 general practitioners, and 20 specialists from other branches of medicine) to understand their views on the management of prediabetes, especially with regards to voglibose. RESULTS AND
CONCLUSION: There was an equivocal response to the question as to whether only diet and exercise were sufficient for the management of prediabetes. Most of the respondents used metformin for the management of prediabetes, while voglibose was the most favoured second-line drug. Almost all the respondents agreed that the approval which voglibose got in Japan for the management of prediabetes was relevant in India as well. Only 51.3% of all respondents had prescribed voglibose for prediabetes. Thus, voglibose appears to be popular second-line drug for the management of prediabetes.

Entities:  

Keywords:  Hypoglycaemia; Metformin; Prediabetes; Voglibose

Year:  2013        PMID: 24298491      PMCID: PMC3843411          DOI: 10.7860/JCDR/2013/5787.3486

Source DB:  PubMed          Journal:  J Clin Diagn Res        ISSN: 0973-709X


  3 in total

1.  Diagnosis and management of prediabetes in the continuum of hyperglycemia: when do the risks of diabetes begin? A consensus statement from the American College of Endocrinology and the American Association of Clinical Endocrinologists.

Authors:  Alan J Garber; Yehuda Handelsman; Daniel Einhorn; Donald A Bergman; Zachary T Bloomgarden; Vivian Fonseca; W Timothy Garvey; James R Gavin; George Grunberger; Edward S Horton; Paul S Jellinger; Kenneth L Jones; Harold Lebovitz; Philip Levy; Darren K McGuire; Etie S Moghissi; Richard W Nesto
Journal:  Endocr Pract       Date:  2008-10       Impact factor: 3.443

Review 2.  Oral antidiabetic drugs and regression from prediabetes to normoglycemia: a meta-analysis.

Authors:  Olivia J Phung; William L Baker; Vanita Tongbram; Adarsh Bhardwaj; Craig I Coleman
Journal:  Ann Pharmacother       Date:  2012-04-03       Impact factor: 3.154

3.  Risk of cardiovascular and all-cause mortality in individuals with diabetes mellitus, impaired fasting glucose, and impaired glucose tolerance: the Australian Diabetes, Obesity, and Lifestyle Study (AusDiab).

Authors:  Elizabeth L M Barr; Paul Z Zimmet; Timothy A Welborn; Damien Jolley; Dianna J Magliano; David W Dunstan; Adrian J Cameron; Terry Dwyer; Hugh R Taylor; Andrew M Tonkin; Tien Y Wong; John McNeil; Jonathan E Shaw
Journal:  Circulation       Date:  2007-06-18       Impact factor: 29.690

  3 in total
  1 in total

1.  Prediabetes Awareness and Practice Among Indian Doctors- A Cross-sectional Study.

Authors:  Asha Basavareddy; Ashwitha Shruti Dass; Sarala Narayana
Journal:  J Clin Diagn Res       Date:  2015-08-01
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.